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Background: Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s triad, is a clinical syndrome
which consists of aspirin (ASA) intolerance, chronic rhinosinusitis with nasal polyposis, and intrinsic bronchial
asthma (Press Med 119:48-51, 1922). ASA challenge is the gold standard for diagnosing AERD (Curr Allergy Asthma
9:155-163, 2009). The practice of ASA challenge and desensitization in Canada is infrequently utilized, which may
explain its omission as a viable therapeutic option in the latest Canadian clinical practice guidelines for acute and
chronic rhinosinusitis (AACI 7:1-38, 2011).
Methods: This retrospective study assessed 111 patients who underwent ASA desensitization in the Allergy and
Immunology clinic at St. Joseph’s Healthcare (SJHC) in London, Ontario. The mean age was 50.7 years, and 52.5%
(n = 58) were male. Sixty-one percent (n = 68) claimed prior, significant reactions to ASA, and all patients had
features of AERD.
Results: Seventy-three percent (n = 81) claimed symptom improvement after achieving maintenance dosing on the
desensitization protocol. Of this population, 21.6% (n = 24) improved in all 3 areas of interest (sense of taste or
smell, upper respiratory symptoms and lower respiratory symptoms). Twenty-six percent (n = 29) had adverse
effects, mostly in the way of gastrointestinal upset, but no severe adverse events were seen.
Conclusions: ASA desensitization helps improve symptoms in patients with AERD. Further, it allows patients to
tolerate additional ASA and other non-steroidal anti-inflammatories (NSAIDs) when needed for supplemental
analgesia or for cardio-protection. This is of particular benefit in those who require these medications for improved
quality of life, and for reduced morbidity and mortality, such as those with cardiovascular disease or chronic pain.
There should be further studies conducted in Canada as well as consideration for ASA desensitization to be
included in the next clinical practice guidelines.
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Aspirin-exacerbated respiratory disease (AERD) is a clinical
syndrome which consists of aspirin intolerance, chronic
rhinosinusitis with nasal polyposis and intrinsic bronchial
asthma as first described by Widal in 1922 [1]. Max
Samter, an American immunologist, revisited the associ-
ation and proposed the possible pathogenesis in the 1960s.* Correspondence: cibrahim@uwo.ca; dmoote@uwo.ca
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unless otherwise stated.His name is often associated with the syndrome—Samter’s
triad [2]. AERD affects 0.3-0.9% of the general population,
but its prevalence rises to 10-20% in asthmatics, and up to
30-40% in asthmatics with nasal polyposis [3,4]. Clinical
features include onset of nasal congestion with anosmia,
with progression to chronic pansinusitis and nasal polyp-
osis. The nasal polyps often re-grow rapidly after repeated
surgeries [5]. Asthma may precede the upper airway dis-
ease or develop later.
ASA challenge is the gold standard for diagnosing
AERD [5]. Zeiss and Lockey were the first authors tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of patients
Age-year, mean (range) 50.7 (17–75)
Male, n (%) 58 (52.2)
Female, n (%) 53 (47.8%)










Baseline FEV1 (n) Post ASA FEV1 (n)
Mild (≥80) 25 32
Moderate (<80 × ≥50) 36 36
Severe (<50) 2 2
Unknown 48 41
Table 2 Indications of disease severity
Prednisone use in past 12 months (%) 63.80%
Antibiotic use in past 12 months (%) 22.90%
Number of endoscopic sinus surgeries (%)
None 11.4
1 to 3 65.7
4 to 6 19.1
7 to 10 1.9
>10 1.9
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lenge in ASA-sensitive patients in 1976 [6]. Since then,
multiple studies have shown that desensitization and daily
treatment with aspirin can not only allow the medication
to be tolerated, but can significantly improve overall symp-
toms and quality of life, decrease formation of nasal polyps
and sinus infections, reduce the need for oral corticoste-
roids and sinus surgery, and improve nasal and asthma
scores in patient with AERD. The effects are noticeable as
early as 4 weeks following desensitization [7], and persist
at least up to 5 years in to follow-up [8]. Much of what we
know about ASA challenge and desensitization derives
from studies of over 1400 patients who have undergone
the procedure at Scripps Clinic in San Diego, CA, USA.
ASA challenge and desensitization has received little atten-
tion in Canada, which may explain its omission as a viable
therapeutic option in the latest Canadian clinical practice
guidelines for acute and chronic rhinosinusitis [9].
Since the use of aspirin desensitization was first de-
scribed in 1984, and shown to clinically improve the
underlying inflammatory airway disease [10], much re-
search has been done to further optimize this procedure.
Premedication with leukotriene receptor antagonists,
alone or in combination with inhaled corticosteroids and
long-acting β2-agonists, was able to reduce lower re-
spiratory tract reactions during aspirin challenge in some
patients, but did not change the overall rate of positive
aspirin challenge and desensitization [11,12].
The aim of this study was two-fold. First, to assess
patient-specific improvement scores and address ques-
tions surrounding patient discontinuation. Second, to as-




This retrospective study of 111 patients took place at the
Allergy and Immunology clinic at St. Joseph’s Healthcare
(SJHC) in London, Ontario, from 2007–2011.
Inclusion criteria involved patients seen in consultation
at the Allergy and Immunology clinic, an adult (≥ age of
17), who had nasal polyposis, asthma, and a history of
ASA or non-steroidal anti-inflammatory (NSAIDs) sensi-
tivity, and had a stable clinical course. They must have then
completed a trial of ASA desensitization and attended
follow-up for at least one year after. Baseline medical ill-
ness and therapies were assessed (Table 1). The use of ste-
roids and antibiotics related to AERD were determined
(Table 2).
Subjects were excluded if they had significant con-
comitant disease, history of life-threatening ASA or
NSAID reactions, or other chronic conditions or treat-
ments that may have confounded the interpretation of
the study results.Ethics approval was received from Western University
in London, Ontario. Informed consent was obtained,
and clinical records were reviewed, looking specifically
for ASA desensitization over a two-day protocol. This
previously validated protocol is from the Scripps Clinic,
with an initial dose of 40 mg titrated up to 162 mg on
day one, and then 325 mg on day two [3,7,8]. From past
literature, maintenance dose is kept at 325 mg or
650 mg twice daily [3,8,13].
Patient characteristics
Patient characteristics prior to ASA challenge and
desensitization were obtained, including age, duration of
Table 4 ASA data
History of ASA reaction (n, %) 64 (61)




*Mixed (flushing, worsening nasal congestion, swelling).
**Significant reaction (anaphylactoid).
Table 5 ASA Desensitization
Total desensitized (n = 111)
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cent predicted FEV1 (Table 1). Further severity of dis-
ease was assessed based on number of prednisone bursts
and antibiotic treatment in the preceding 12 months to
desensitization, current asthma and rhinitis controller
medications, number of endoscopic sinus operations,
and severity of disease on imaging (Tables 2 and 3).
Types of reactions during desensitization were re-
corded and classified based on the data available
(Table 4), as was medication used prior to and during
desensitization (Table 5). Any adverse reactions to
continued ASA use, and reasons for discontinuation of
therapy were also assessed, and analyzed, as provided
through chart review.
Outcomes assessment
A priori rules were used regarding clinical benefit of
ASA desensitization through patient statements, clinical
notes, and imaging. Although ideal to compare imaging
pre- and post- desensitization, the time interval and
completeness of each patient was variable, and/or con-
founded by repeated surgical intervention or patient
withdrawal. These data will be collected for a future,
prospective study. Initial CT imaging was scored via the
validated Lund-MacKay CT score (Table 2).
Assessment of safety
Given the potential for significant reactions in a patient
with known sensitivity to ASA and/or NSAIDs, the
desensitization process was done in a controlled setting
in hospital, with medications, including epinephrine
close at hand. It was carried out using a validated proto-
col [3], conducted in a step-wise approach, with safety as
a priority. Subjects were monitored closely by the physi-
cians and nurses. Vital signs and physical examinationsTable 3 Asthma and rhinitis medications
Skin test positivity (%) 63.8
Baseline asthma therapy (%) Post-ASA asthma therapy (%)
SABA 1.9 SABA 2.7
ICS 2.9 ICS 3.6
LABA 0.0 LABA 0.0
Leukotriene 1.9 Leukotriene 4.5
Combination 80.0 Combination 60.4
Unknown 13.3 Unknown 28.8
Baseline rhinitis therapy (%) Post ASA rhinitis therapy (%)
Nasal washes 3.8 Nasal washes 2.7
Nasal steroids 46.7 Nasal steroids 46.8
Antihistamines 2.9 Antihistamines 0.9
Combination 28.6 Combination 19.0
Unknown 18.0 Unknown 30.6were taken, at a minimum, before and after each interval
dose. Subjects were monitored for at least 1 hour after
last dose of the day.
Statistical analysis
Statistical analysis was performed using SAS 9.3 (SAS
Institute, Cary, NC) and through Microsoft Excel™, in-




The median age was 50.7 (17–75), and the population was
split between males at 52.2% (n = 58) and females at 47.8%
(n = 53). Most of the population had upper respiratoryOral Steroid 21
Puffer (SABA, ICS, combination) 13
Epinephrine 1




Patient improvement score (out of 3)
Change in taste or smell (1 pt) 34/111
Change in upper respiratory symptoms (1 pt) 78/111
Change in lower respiratory symptoms (1 pt) 67/111
0 out of 3 17 (15.3)
1 out of 3 20 (18.1)
2 out of 3 45 (40.5)
3 out of 3 24 (21.6)
Unknown 5 (4.5)
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(66.3%, n = 74) for over 5 years. Based on limited retro-
spective data, it was difficult to assess baseline FEV1 se-
verity and to assess for significant change during ASA
desensitization.
In regards to baseline therapy, 80.8% (n = 90) were on
a combination therapy for asthma, and 46.7% (n = 52)
were on nasal steroids for rhinitis symptoms. After
desensitization, there were comments in the patients
record about being on less therapy, and the data trended
towards decreased upper and lower respiratory therapy
once on maintenance ASA therapy, but this did not
reach statistical significance. As per the validated proto-
col [3], patients were started on 40 mg and titrated up
to 162 mg on day one. On the second day, they were ti-
trated up to 325 mg. From there the maintenance dose
was 325 mg or 650 mg twice daily (Table 6).
In terms of AERD features, overall this population
trended towards having more moderate-severe disease.
Sixty-four percent (n = 71) required oral steroid therapy
within the 12 months prior to desensitization therapy
and 22.9% (n = 25) required antibiotics. The majority of
the population, as seen in Table 2, had undergone more
than one endoscopic sinus surgery, and most showed
severe sinus of disease on imaging. This was confirmed
by the severity in the Lund-MacKay score prior to
desensitization with 97.4% (n = 108) scored ≥13 points.Outcomes assessment
Sixty-one percent (n = 68) had recorded previous reac-
tions to ASA and/or NSAIDs exposure (Table 4).
Of those desensitized, 35.1% (n = 39) received pre-
treatment or required treatment during desensitization,
most commonly the use of an oral steroid (21/39 persons).
One patient required epinephrine during the procedure,
but was able to continue with the planned day twoTable 6 ASA Maintenance therapy, need for
resensitization, and sinus surgery during therapy
ASA maintenance Dose (mg)* BID (n, %) TID (n, %)
325 37/80 (46.3%) 6/80 (7.5%)







1st year (n, %) 2nd year (n, %) 3rd year (n, %)
15/111 (13.5%) 5/80 (6.3%) 6/80 (7.5%)
Note:
- N = 80 includes all those who achieved desensitization up to 1 year, with 10
lost to follow up, but kept as ‘intention to treat’.
- N = 111, includes all those who initially achieved desensitization.
*Reasons for ASA dose variations included: adverse effects, up- or down-titrated
to symptoms or lack thereof, and/or interruption for surgery or illness.
**Reasons for resensitization included: restart post infection, sinus surgery,
other surgery, and/or compliance.protocol and was successful in achieving desensitization
and eventual improvement in symptoms.
Of those who achieved maintenance therapy, 73%
(n = 81) stated improvement in symptoms of AERD.
We created a patient improvement score with 1 point
for improvement in taste or smell, 1 point for improve-
ment in upper respiratory symptoms, and 1 point for
improvement in lower respiratory symptoms for a total out
of 3. Fifteen percent (n = 17) had no benefit, 18.1% (n = 20)
had improvement in only one area, 40.5% (n = 45) had im-
provement in two areas, and 21.6% (n = 24) had improve-
ment in all three.
Safety assessment
In other published studies, known adverse effects occurred
during the desensitization process (chest symptoms, wors-
ened nasal congestion, rhinorrhea, facial flushing). In our
study, one patient developed an anaphylactic reaction re-
quiring epinephrine and prednisone. However, when re-
challenged the patient on day 2 and they tolerated the dose
of ASA, and did not require further rescue therapy. There
has been anecdotal evidence that the more significant the
adverse reaction, the more likely the subject is to have clin-
ically significant improvement with desensitization, how-
ever, no study has specifically assessed this.
Of those who initially tolerated ASA maintenance
therapy, 26.1% (n = 29) eventually developed adverse re-
actions (Table 7). Most common was gastrointestinal
upset (n = 23). Of this group, 8 patients had a history of
gastrointestinal reflux, on a proton-pump inhibitor, and
3 patients required the addition of a proton-pump in-
hibitor. Three patients had issues with easy bruising.
Twelve months after desensitization, 27.9% (n = 31) had
discontinued therapy. The most common reasons cited in-
cluded lack of patient-perceived benefit, lack of compli-
ance and thus subsequent need for repeat desensitization,
worsened respiratory symptoms, or intolerable side-effects
related to high-dose ASA.
Discussion
This retrospective analysis looked at 111 patients who
underwent ASA desensitization for AERD, who were
followed for a maintenance period of approximately
12 months.
In regards to the first objective, of those who achieved
maintenance therapy, 73% (n = 81) claimed symptom im-
provement. There was improvement noted in the chart re-
view of overall symptoms, quality of life, and reduced need
for rescue therapy for upper and lower respiratory symp-
toms. Patients were particularly impressed with any return
of their sense of smell and/or taste. Using a score out of 3,
relating to improved AERD symptoms, 15.3% (n = 17)
identified no benefit, however, the remaining 94 pa-
tients had some form of improvement, with 21.6% (n =
Table 7 Adverse reactions and discontinuation of ASA














*Most common reasons for discontinuation: patient belief not working,
compliance, worsening symptoms, infection, surgery, and/or adverse effects.
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taste/smell, upper, and lower respiratory symptoms.
These values are similar to those seen in the literature.
A retrospective study by Berges-Gimeno et al. [8] of 172
patients found a statistically significant improvement in
the number of sinus infections, ability to smell, and
upper and lower respiratory symptoms after one year of
maintenance ASA therapy. There were also fewer hospi-
talizations for asthma, and a reduction in the use of
nasal, inhaled and oral corticosteroids. Overall, 87% were
said to have responded to ASA therapy.
A randomized, double blind study by Swierczynska-
Krepa M et al. [14] found improved smell, peak nasal
inspiratory flow, and quality of life amongst aspirin-
intolerant asthma patients on ASA maintenance.
A randomized controlled trial by Lee et al. [13], took
137 patients randomized to receive ASA 325 mg or
625 mg twice daily. Then after 1 month the group either
increased or decreased their dosage based on symptoms.
There was a statistically significant improvement in sinus
infections and operations, hospitalizations for asthma, and
upper and lower respiratory symptoms. After one year,
there was a statistically significant reduction in intranasal
and oral corticosteroid use.
In our study, patients were mostly on ASA 325 mg or
650 mg twice daily (Table 6). Overall, 46.3% were on
325 mg twice daily, and 46.3% were taking 650 mg twice
daily. Six patients (7.5%) were on 325 mg three times
daily, as they were in-between dosage adjustments. Dos-
age adjustments varied based on a multitude of factors
such as adequate or inadequate symptom control, ad-
verse effects, compliance, and interruptions for surgery
or illness.It is difficult to say that the ideal dose is, and the lit-
erature has shown benefit for both regimens [3,5,13]. As
such, it becomes an area of individualized therapy based
on patient response.
Overall this study had a patient population with se-
vere AERD, and many with a history of multiple nasal
surgeries (Table 2). The literature has shown that ASA
desensitization has resulted in improved nasal polyposis
and less nasal surgeries [5,15]. A recent study by Cho
et al. [16] demonstrated a sustained improvement in
endoscopic and symptomatic nasal polyposis symptoms
of those on ASA maintenance therapy.
In our study, fifteen patients (13.5%) underwent nasal
surgery within the first year of desensitization. Then 6.3%
and 7.5% underwent nasal surgery within the second and
third years of desensitization, respectively (Table 6).
In our study, at the end of 12 months, 27.9%, (n = 31)
had discontinued therapy. Two of those patients were
asked to discontinue therapy for upcoming surgery. An-
other two stopped due to infection, with the inability to
maintain therapy. Otherwise, the rest who discontinued
therapy claimed lack of perceived benefit, issues with
compliance of high-dose ASA twice a day, worsened
AERD symptoms, or adverse effects related to ASA
therapy.
Among those who tolerated ASA therapy, 26.1% (n = 29)
had adverse events that were likely due to the ASA. Most
commonly this was gastrointestinal upset, and a few pa-
tients needed to be started on proton-pump-inhibitor
therapy. Three patients had issues with easy bruising, 1
with tinnitus, 1 patient developed gout, and 1 patient had
worsened hypertension. There were no life-threatening
adverse reactions during the 12-month follow up. This is a
similar to past literature where 10-50% of patients discon-
tinue, and 20-30% complain about gastritis and reflux
symptoms [3,6,8].
The retrospective study by Berges-Gimeno et al. [8]
showed that 13% discontinued, with 67% of that group
having gastrointestinal symptoms. Of the 172 patients,
11% failed to respond to therapy.
From the randomized study by Lee et al. [13], 23.4%
discontinued due to adverse effects, with 37.5% of that
group having dyspepsia.
Limitations in this study include those associated with
any retrospective study and analysis, particularly lack of
data points, such as pre- and post- FEV1 percent-
predicted values. A randomized controlled trial would
have been the preferred method. Additionally, not all pa-
tients were initially challenged to prove ASA sensitivity,
rather the focus was on clinical history. Dosing was car-
ried out by different physicians and not controlled for.
In assessing response to ASA maintenance therapy,
there was no objective and validated scoring system
used. Lastly, follow-up was only 12 months, and it would
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gitudinally to assess benefit-risk ratios for clinical out-
comes versus adverse effects. Pre- and post- CT sinus
imaging may have provided a better diagnostic assess-
ment of the effectiveness of desensitization therapy,
however post-therapy imaging is not the current stand-
ard of care, nor is there sufficient data to correlate the
association between symptoms and imaging on post-
therapy images.
With respect to future directions, a prospective, ran-
domized controlled study, would be beneficial to gather
key clinical data points, as well, to assess baselines charac-
teristics, prove ASA sensitivity, and determine if there are
certain clinical predictors that indicate which patients
would be better candidates for ASA desensitization. In
previous studies, those who were able to maintain a high-
dose ASA regimen successfully were more likely to be: less
than 40 years old, a poor sense of smell, multiple prior re-
spiratory reactions, or to have had severe prior asthmatic
reactions associated with aspirin and NSAIDs [15]. How-
ever, to our knowledge, there is no published literature on
validated and reproducible patient predictors of clinical
benefit from ASA desensitization.
Conclusion
This study assessing 111 patients who underwent ASA
desensitization for AERD showed overall effectiveness,
with 81/111 patients claiming improvement in symptoms
and 31/111 discontinuing maintenance ASA therapy. This
is the first Canadian study assessing ASA desensitization
and maintenance therapy in the AERD population. A vali-
dated protocol is in place, and many centres outside of
Canada have significant reproducible data showing benefit
to ASA desensitization in this population.
The ability to desensitize the patient to ASA not only
aids in symptom improvement and a gain in quality of life
in this population, but it also allows the use of ASA and
NSAIDs in patient populations who require these medica-
tions for other reasons. We believe ASA desensitization
should be considered and performed more frequently in
the appropriate clinical situations in Canada.Competing interests
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